Heterogeneity in Economic Value of SGLT2is for Type 2 Diabetes: Subgroup Modeling Cost-Effectiveness Analyses.
K. Chong,Chun-Ting Yang,2 Authors,S. Kuo
2025 · DOI: 10.1007/s40273-025-01536-6
PharmacoEconomics (Auckland) · 0 Citations
TLDR
The analysis suggests that adopting SGLT2is over DPP4is for T2D is highly cost-effective across patient subgroups, particularly for the elderly and patients with mild renal impairment.
Cited Papers
Citing Papers